Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Alpine Immune Sciences (ALPN) News Today

Alpine Immune Sciences logo
Alpine Immune Sciences, Inc. stock logo
BNP Paribas Financial Markets Buys 93,423 Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN)
BNP Paribas Financial Markets grew its position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 691.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 106,941 shares of the biotechnology company's stock after buying a
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences (NASDAQ:ALPN) Reaches New 12-Month High at $65.00
Alpine Immune Sciences (NASDAQ:ALPN) Sets New 1-Year High at $65.00
Alpine Immune Sciences, Inc. stock logo
Jump Financial LLC Buys Shares of 55,720 Alpine Immune Sciences, Inc. (NASDAQ:ALPN)
Jump Financial LLC bought a new position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 55,720 shares of the biotechnology company's stock, valued at approximately $1,062,00
What 11 Analyst Ratings Have To Say About Alpine Immune Sciences
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences (NASDAQ:ALPN) Given "Neutral" Rating at Wedbush
Wedbush reissued a "neutral" rating and set a $65.00 price objective on shares of Alpine Immune Sciences in a report on Thursday.
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives Consensus Recommendation of "Hold" from Analysts
Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Get Free Report) have received a consensus rating of "Hold" from the eleven analysts that are covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and three have assigned a bu
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences (NASDAQ:ALPN) Reaches New 52-Week High at $64.96
Alpine Immune Sciences (NASDAQ:ALPN) Hits New 12-Month High at $64.96
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Sees Significant Drop in Short Interest
Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Get Free Report) saw a significant decline in short interest in April. As of April 30th, there was short interest totalling 3,890,000 shares, a decline of 17.9% from the April 15th total of 4,740,000 shares. Based on an average daily trading volume, of 2,230,000 shares, the short-interest ratio is currently 1.7 days.
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences (NASDAQ:ALPN) Sees Large Volume Increase
Alpine Immune Sciences (NASDAQ:ALPN) Sees Large Volume Increase
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Sold by Vivo Capital LLC
Vivo Capital LLC lowered its holdings in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 10.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 819,275 shares of the biotechnology company's stock after
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences (NASDAQ:ALPN) Sets New 52-Week High at $64.72
Alpine Immune Sciences (NASDAQ:ALPN) Sets New 12-Month High at $64.72
Alpine Immune Sciences Inc
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences (NASDAQ:ALPN) Sets New 1-Year High at $64.70
Alpine Immune Sciences (NASDAQ:ALPN) Sets New 12-Month High at $64.70
Alpine Immune Sciences, Inc. stock logo
Vivo Capital LLC Sells 298,770 Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN)
Vivo Capital LLC lessened its stake in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 36.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 520,505 shares of the biotechnology company's stock after selling 298,770 shares duri
Alpine Immune Sciences, Inc. (ALPN)
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences (NASDAQ:ALPN) Sets New 1-Year High at $64.58
Alpine Immune Sciences (NASDAQ:ALPN) Sets New 12-Month High at $64.58
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences (NASDAQ:ALPN) Given "Hold" Rating at TD Cowen
TD Cowen reaffirmed a "hold" rating on shares of Alpine Immune Sciences in a research note on Tuesday.
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Bought by Vanguard Group Inc.
Vanguard Group Inc. increased its holdings in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 5.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,474,879 shares of the biotechnology company's stock after
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences (NASDAQ:ALPN) Downgraded by Leerink Partnrs to Market Perform
Leerink Partnrs cut Alpine Immune Sciences from an "outperform" rating to a "market perform" rating in a report on Thursday.
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences' (ALPN) "Market Perform" Rating Reaffirmed at SVB Leerink
SVB Leerink reissued a "market perform" rating and set a $65.00 price target (up previously from $42.00) on shares of Alpine Immune Sciences in a research report on Friday.
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences (NASDAQ:ALPN) Downgraded by HC Wainwright
HC Wainwright downgraded Alpine Immune Sciences from a "buy" rating to a "neutral" rating in a report on Thursday.
Alpine Immune Sciences, Inc. stock logo
Alpine Immune Sciences' (ALPN) "Neutral" Rating Reaffirmed at Wedbush
Wedbush reaffirmed a "neutral" rating on shares of Alpine Immune Sciences in a research report on Thursday.
Alpine Immune Sciences soars on $4.9bn Vertex takeover
Get Alpine Immune Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.

Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)

You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.

Click Here to get the full details about Crypto’s Hidden Gem

ALPN Media Mentions By Week

ALPN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ALPN
News Sentiment

0.00

0.60

Average
Medical
News Sentiment

ALPN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ALPN Articles
This Week

0

5

ALPN Articles
Average Week

Get Alpine Immune Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ALPN) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners